PFE Stock Today (Nov. 25, 2025): Pfizer Rises on Metsera Obesity Deal, PADCEV Approval and Options Surge
Pfizer shares rose 1.7% to $25.65 by early afternoon Tuesday after the company completed a $10 billion acquisition of obesity-drug developer Metsera. The stock traded between $25.24 and $25.96, with a market cap near $143 billion. Pfizer also reported new FDA approval for PADCEV plus Keytruda in bladder cancer and continued strong options activity at the $25 strike.